Journal of International Oncology ›› 2023, Vol. 50 ›› Issue (9): 532-539.doi: 10.3760/cma.j.cn371439-20230428-00102
• Original Articles • Previous Articles Next Articles
Xie Yu, Jiang Cheng, Huang Mingmin, Guo Aibin, Yin Zhenyu, Lin Yongjuan()
Received:
2023-04-28
Revised:
2023-07-05
Online:
2023-09-08
Published:
2023-10-26
Contact:
Lin Yongjuan
E-mail:lingyongjuan0218@126.com
About author:
First author contact:Xie Yu and Jiang Cheng are contributed equally to the article
Supported by:
Xie Yu, Jiang Cheng, Huang Mingmin, Guo Aibin, Yin Zhenyu, Lin Yongjuan. Effects of intrathecal infusion chemotherapy on intracranial pressure in non-small cell lung cancer patients with leptomeningeal metastases by ultrasound measurement of optic nerve sheath diameter[J]. Journal of International Oncology, 2023, 50(9): 532-539.
"
临床病理特征 | 结果 | 临床病理特征 | 结果 |
---|---|---|---|
性别 | 抗肿瘤治疗方案b | ||
男 | 14(45.16) | 奥希替尼/伏美替尼/阿美替尼 | 26(70.27) |
女 | 17(54.84) | TAS6417 | 2(6.45) |
年龄(岁) | AZD3759 | 4(12.90) | |
≤53 | 12(38.71) | 达克替尼/阿法替尼 | 4(12.90) |
>53 | 19(61.29) | 易瑞沙 | 2(6.45) |
BMI(kg/m2) | 21.75±2.74 | 克唑替尼 | 1(3.23) |
心率(次/min) | 79.39±12.23 | 赛沃替尼 | 1(3.23) |
平均动脉压(mmHg) | 89.28±10.98 | 白蛋白紫杉醇 | 1(3.23) |
颅内压(mmH2O) | 218.55±63.83 | KPS评分(分) | |
吸烟史 | <60 | 14(45.16) | |
有 | 13(41.94) | ≥60 | 17(54.84) |
无 | 18(58.06) | 头痛评分(分) | |
确诊肺癌至发生LM时间(月) | ≤2 | 23(74.19) | |
≤24 | 20(64.52) | >2 | 8(25.81) |
>24 | 11(35.48) | RANO评分(分) | |
LM临床症状a | <4 | 13(41.94) | |
头痛、恶心、呕吐 | 27(87.10) | ≥4 | 18(58.06) |
肢体乏力、麻木 | 5(16.13) | 典型MRI异常 | |
颅神经障碍 | 14(45.16) | 是 | 26(83.87) |
癫痫 | 4(12.90) | 否 | 5(16.13) |
颈项强直 | 6(19.35) | 脑脊液细胞学阳性 | |
合并脑转移 | 是 | 25(80.65) | |
是 | 13(41.94) | 否 | 6(19.35) |
否 | 18(58.06) |
"
时间点 | MAP(mmHg) | 心率(次/min) | 头痛评分(分) |
---|---|---|---|
T0 | 89.80(83.40,93.67) | 80.00(75.00,84.50) | 2.00(0.50,3.00) |
T1 | 95.00(80.83,99.37) | 80.00(72.50,87.50) | 2.00(1.00,3.00) |
T2 | 91.86(79.88,100.14) | 74.00(66.00,87.50) | 2.00(2.00,3.00) |
T3 | 90.15(79.04,100.55) | 82.00(72.00,90.00) | 2.00(1.00,3.00) |
T4 | 105.14(88.55,114.74)a | 80.00(70.50,90.00) | 2.00(1.00,2.00) |
T5 | 98.96(81.72,111.81) | 77.00(68.00,91.00) | 2.00(1.00,2.00) |
T6 | 89.29(85.45,100.38) | 77.00(71.50,88.50) | 2.00(0.00,2.00) |
χ2值 | 16.11 | 2.18 | 11.64 |
P值 | 0.013 | 0.902 | 0.071 |
"
时间点 | 左眼 | 右眼 | 双眼 | |||||
---|---|---|---|---|---|---|---|---|
ONSD(mm) | ICPONSD(mmH2O) | ONSD(mm) | ICPONSD(mmH2O) | ONSD(mm) | ICPONSD(mmH2O) | |||
T0 | 5.85±0.64 | 222.81±56.81 | 5.85±0.12 | 223.26±58.33 | 5.85±0.64 | 223.03±57.24 | ||
T1 | 5.72±0.68 | 211.89±60.29 | 5.89±0.12 | 227.08±61.68 | 5.81±0.64 | 219.49±57.24 | ||
T2 | 7.11±1.11a | 335.12±98.32a | 6.93±0.20a | 319.36±101.10a | 7.02±1.03a | 327.24±91.56a | ||
T3 | 6.42±0.78 | 274.17±68.87 | 6.40±0.14 | 272.33±69.61 | 6.41±0.75 | 273.25±67.04 | ||
T4 | 5.69±0.63 | 208.77±56.12 | 5.71±0.12 | 211.21±57.73 | 5.70±0.63 | 209.99±56.26 | ||
T5 | 5.61±0.64 | 201.75±56.79 | 5.66±0.12 | 206.51±57.22 | 5.64±0.63 | 204.13±56.29 | ||
T6 | 5.65±0.88 | 205.59±78.36 | 5.33±0.14 | 177.22±68.98 | 5.49±0.76 | 191.40±67.95 | ||
F值 | 58.48 | 58.48 | 49.34 | 49.34 | 78.05 | 78.13 | ||
P值 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
[1] | Mo F, Pellerino A, Soffietti R, et al. Blood-brain barrier in brain tumors: biology and clinical relevance[J]. Int J Mol Sci, 2021, 22(23): 12654. DOI: 10.3390/ijms222312654. |
[2] | Cheng H, Perez-Soler R. Leptomeningeal metastases in non-small-cell lung cancer[J]. Lancet Oncol, 2018, 19(1): e43-e55. DOI: 10.1016/S1470-2045(17)30689-7. |
[3] | Li H, Zheng S, Lin Y, et al. Safety, pharmacokinetic and clinical activity of intrathecal chemotherapy with pemetrexed via the Ommaya reservoir for leptomeningeal metastases from lung adenocarcinoma: a prospective phase Ⅰ study[J]. Clin Lung Cancer, 2023, 24(2): e94-e104. DOI: 10.1016/j.cllc.2022.11.011. |
[4] | Fan C, Zhao Q, Li L, et al. Efficacy and safety of intrathecal pemetrexed combined with dexamethasone for treating tyrosine kinase inhibitor-failed leptomeningeal metastases from EGFR-mutant NSCLC—a prospective, open-label, single-arm phase 1/2 clinical trial (unique identifier: ChiCTR1800016615)[J]. J Thorac Oncol, 2021, 16(8): 1359-1368. DOI: 10.1016/j.jtho.2021.04.018. |
[5] | Ozcan G, Singh M, Vredenburgh JJ. Leptomeningeal metastasis from non-small cell lung cancer and current landscape of treatments[J]. Clin Cancer Res, 2023, 29(1): 11-29. DOI: 10.1158/1078-0432.CCR-22-1585. |
[6] | Eide PK, Mariussen E, Uggerud H, et al. Clinical application of intrathecal gadobutrol for assessment of cerebrospinal fluid tracer clearance to blood[J]. JCI Insight, 2021, 6(9): e147063. DOI: 10.1172/jci.insight.147063. |
[7] |
Stearns LM, Abd-Elsayed A, Perruchoud C, et al. Intrathecal drug delivery systems for cancer pain: an analysis of a prospective, multicenter product surveillance registry[J]. Anesth Analg, 2020, 130(2): 289-297. DOI: 10.1213/ANE.0000000000004425.
pmid: 31567325 |
[8] | Jiang C, Lin Y, Li H, et al. Bedside ocular ultrasonography for diagnosing increased intracranial pressure in patients with leptomeningeal metastases from non-small-cell lung cancer[J]. Cancer Med, 2023, 12(6): 6913-6923. DOI: 10.1002/cam4.5484. |
[9] | Le Rhun E, Weller M, Brandsma D, et al. EANO-ESMO clinical practice guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours[J]. Ann Oncol, 2017, 28(suppl_4): iv84-iv99. DOI: 10.1093/annonc/mdx221. |
[10] |
Yamashiro S, Hitoshi Y, Tajiri S, et al. Palliative lumboperitoneal shunt for leptomeningeal metastasis-related hydrocephalus: a case series[J]. Palliat Med, 2017, 31(1): 93-96. DOI: 10.1177/0269216316649128.
pmid: 27188875 |
[11] | Su YH, Chiang CL, Yang HC, et al. Cerebrospinal fluid diversion and outcomes for lung cancer patients with leptomeningeal carcinomatosis[J]. Acta Neurochir (Wien), 2022, 164(2): 459-467. DOI: 10.1007/s00701-021-04763-w. |
[12] |
Zhou T, Zhu S, Xiong Q, et al. Intrathecal chemotherapy combined with systemic therapy in patients with refractory leptomeningeal metastasis of non-small cell lung cancer: a retrospective study[J]. BMC Cancer, 2023, 23(1): 333. DOI: 10.1186/s12885-023-10806-5.
pmid: 37041504 |
[13] | Geng D, Guo Q, Huang S, et al. A retrospective study of intrathecal pemetrexed combined with systemic therapy for leptomeningeal metastasis of lung cancer[J]. Technol Cancer Res Treat, 2022, 21: 15330338221078429. DOI: 10.1177/15330338221078429. |
[14] | Ma Y, Liu H, Zhang M, et al. Successful treatment using targeted therapy, radiotherapy, and intrathecal chemotherapy in a patient with leptomeningeal metastasis with an epidermal growth factor receptor exon 20 insertion mutation: a case report[J]. Ann Palliat Med, 2022, 11(4): 1533-1541. DOI: 10.21037/apm-21-321. |
[15] | Korsbæk JJ, Beier D, Hagen SM, et al. Psychiatric comorbidities in patients with idiopathic intracranial hypertension: a prospective cohort study[J]. Neurology, 2022, 99(2): e199-e208. DOI: 10.1212/WNL.0000000000200548. |
[16] | Gültekin H, Güven M. Optic nerve sheath diameter, intensive care unit admission and COVID-19-related-in-hospital mortality[J]. QJM, 2023, 116(2): 107-113. DOI: 10.1093/qjmed/hcac242. |
[17] | Vijay P, Lal BB, Sood V, et al. Dynamic optic nerve sheath diameter (ONSD) guided management of raised intracranial pres-sure in pediatric acute liver failure[J]. Hepatol Int, 2021, 15(2): 502-509. DOI: 10.1007/s12072-021-10139-0. |
[18] | Wang LJ, Zhang Y, Li C, et al. Ultrasonographic optic nerve sheath diameter as a noninvasive marker for intracranial hypotension[J]. Ther Adv Neurol Disord, 2022, 15: 17562864211069744. DOI: 10.1177/17562864211069744. |
[19] | Youm JY, Lee JH, Park HS. Comparison of transorbital ultrasound measurements to predict intracranial pressure in brain-injured patients requiring external ventricular drainage[J]. J Neurosurg, 2022, 136(1): 257-263. DOI: 10.3171/2021.1.JNS204218. |
[20] |
Hong J, Kim JS, Lee YH. The effect of normal saline injection volumes on the optic nerve sheath diameter during thoracic epidural analgesia[J]. Pain Physician, 2021, 24(7): E1007-E1013.
pmid: 34704711 |
[21] | Yildiz G, Acar N, Cevik AA, et al. The evaluation of intracranial pressure evaluation by optic nerve sheath diameter measurement on bedside ultrasonography after ischemic stroke[J]. Clin Neurol Neurosurg, 2021, 209: 106914. DOI: 10.1016/j.clineuro.2021.106914. |
[22] | 林永娟, 蒋澄, 卞征, 等. 超声测量视盘联合视神经鞘在评估肺癌软脑膜转移高颅压中的作用[J]. 中国中医眼科杂志, 2023, 33(2): 116-122. DOI: 10.13444/j.cnki.zgzyykzz.2023.02.004. |
[23] | Le Rhun E, Devos P, Winklhofer S, et al. Prospective validation of a new imaging scorecard to assess leptomeningeal metastasis: a joint EORTC BTG and RANO effort[J]. Neuro Oncol, 2022, 24(10): 1726-1735. DOI: 10.1093/neuonc/noac043. |
[24] |
Hoffman H, Abi-Aad K, Bunch KM, et al. Outcomes associated with brain tissue oxygen monitoring in patients with severe traumatic brain injury undergoing intracranial pressure monitoring[J]. J Neurosurg, 2021, 135(6): 1799-1806. DOI: 10.3171/2020.11.JNS203739.
pmid: 34852324 |
[1] | Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266. |
[2] | Wang Kun, Zhou Zhongxin, Zang Qiwei. Predictive value of serum TGF-β1 and VEGF levels in patients with non-small cell lung cancer after single-port thoracoscopic radical resection [J]. Journal of International Oncology, 2024, 51(4): 198-203. |
[3] | Yan Aiting, Wang Cuizhu, Liu Chungui, Lu Xiaomin. Clinical efficacy and safety of camrelizumab and sintilimab in the treatment of advanced non-small cell lung cancer [J]. Journal of International Oncology, 2024, 51(3): 137-142. |
[4] | Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao. Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes [J]. Journal of International Oncology, 2024, 51(3): 143-150. |
[5] | Li Shuyue, Ma Chenying, Zhou Juying, Xu Xiaoting, Qin Songbing. Progress of radiotherapy in oligometastatic non-small cell lung cancer [J]. Journal of International Oncology, 2024, 51(3): 170-174. |
[6] | Zhang Keping, Zhao Yongsheng, Yang Juan, Fu Maoyong. Chlorogenic acid induces mitochondrial dysfunction in lung cancer A549 cells by inhibiting the PI3K-Akt pathway [J]. Journal of International Oncology, 2024, 51(1): 21-28. |
[7] | Zhao Xin, Fan Xuewu, Tian Long, Hu Yimin. Application and evaluation study of 3D ultrasound in image guided radiotherapy for prostate cancer [J]. Journal of International Oncology, 2024, 51(1): 43-49. |
[8] | Feng Chengtian, Huang Furong, Cao Shiyu, Wang Jianyu, Nanding Abiyasi, Jiang Yongdong, Zhu Juanying. Relationships between HER2 protein expression and imaging features in HER2 positive breast cancer patients [J]. Journal of International Oncology, 2023, 50(9): 527-531. |
[9] | Deng Juanjun, Zhao Dayong, Li Miao. Adverse reactions and risk factors of immune checkpoint inhibitors in the treatment of non-small cell lung cancer [J]. Journal of International Oncology, 2023, 50(9): 564-568. |
[10] | Yuan Xiaobin, Wang Yang, Yang Min, Wu Pengxiang, Shen Zhilin, Ma Yongbin, Ding Lieming. Analyzing and monitoring real-world clinical safety of ensartinib for the treatment of patients with ALK-positive non-small cell lung cancer [J]. Journal of International Oncology, 2023, 50(3): 150-156. |
[11] | Zhang Jingxian, Su Jianfei, Wei Xueqin, Yi Dan, Li Xiaojiang. Treatment status of non-small cell lung cancer with METexon14 skipping mutation [J]. Journal of International Oncology, 2023, 50(1): 37-41. |
[12] | Song Tongjun, Deng Rui, Fei Lei, Lei Jinhua, Cao Fengjun. Comparison of the efficacy and safety of percutaneous needle biopsy of pulmonary or pleural lesions guided by CT and ultrasound [J]. Journal of International Oncology, 2022, 49(9): 526-531. |
[13] | Wu Jiayu, Liu Jiacheng. Research progress of radiomics toward lung adenocarcinoma manifesting as solitary ground glass nodule [J]. Journal of International Oncology, 2022, 49(8): 449-452. |
[14] | Gao Junrong, Cao Manqing, Deng Yinghong. Advances in the diagnosis and treatment of hepatocellular carcinoma with contrast-enhanced ultrasound [J]. Journal of International Oncology, 2022, 49(7): 425-429. |
[15] | Zhang Yan, Pan Lei, Liu Shuting. Establishment of an efficacy prediction model for gefitinib in non-small cell lung cancer patients based on ABCB1 and ABCG2 gene polymorphisms [J]. Journal of International Oncology, 2022, 49(6): 327-333. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||